Estudios GETECCU/ENEIDA que serán presentados en la UEGWeek

Archivado en Noticias

Comunicaciones de ESTUDIOS ENEIDA aceptados para UEGW19

Orales

Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
M. Calafat. Hospital Universitario Germans Trias i Pujol

Pósters de estudios promovidos por GETECCU aceptados para UEGW19

Methotrexate after Anti TNF failure in Crohn’s Disease: a retorspectiva series from the ENEIDA registry. Teaching an old dog new tricks? “Poster of excelellence” para ser presentado en la sesión “Posters in the Spotligh”. F. Mesonero. Hospital Universitario Ramón y Cajal.

Is the switch to a second thiopurine a safe strategy in elderlyl patients with Inflammatory bowel disease? A Multicentre cohort study of the ENEIDA registry
M. Calafat. Hospital Universitario Germans Trias i Pujol

Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU
M. Chaparro et al on behalf of the EpidemIBD group

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
M. Chaparro et al on behalf of the PREDICROHN study group from GETECCU.

Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper digestive tract involvement (CROHNEX study)
E. Sainz Arnau. Hospital Sant Joan de Déu Althaia – Manresa

A multicentric study on the effectiveness of Anti – TNF agents in symptomatic stricturing Crohn’s disease

I. Rodríguez – Lago. Hospital Universitario de Galdakao – Usansolo

archivado en Noticias | publicado el 12 de julio de 2019 | última actualización: 26 de julio de 2019 09:53
Formación EII
Canal de GETECCU en YouTube
Base de datos ENEIDA
Nuestros patrocinadores|lea nuestra política de patrocinio